10/10 ATORVA PLUS
10/10 ATORVA PLUS
enzyme responsible for conversion of (HMG – COA) to Mevalonate, a precursor of sterols including
cholesterol.
- Atorvastatin is rapidly absorbed after oral administration , plasma concentrations(Cmax) occure
within 1-2 hours
- More than 98% of Atorvastatin is bond to plasma proteins.
- Atorvastatin undergoes an extensive metabolism to active ortho and para metabolites hydroxylated
which 70% of circulatory inhibitory activity of HMG -COA reductase is attributed to active
metabolites .
- Atorvastatin is eliminated primarily in bile following hepatic and / or extrahepatic metabolism.
- Mean plasma elimination half – life of Atorvastatin in humans is approximately 14 hours.
- The half life of inhibotry activity for HMG-COA reductase is approximately 20-30 hours due to the
contribution of active metabolites.
- Ezetimibe is a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of
cholesterol and related phytosterols.
- Ezetimibe is absorbed and extensively conjugated to pharmacologically Active phenolic glucoronide
(Ezetimibe glucoronide).
- Ezetimibe and Ezetimibe glucoronide are highly bound (90 %) to human plasma proteins.
- Ezetimibe is primary metabolized in small intestinal and liver via glucoronide conjugation with
subsequent billary and renal excretion.
Indication
Dosage & Administration
*liver effects:-
- liver function Should be tested prior the initiation of therapy and at 12 weak following initiation of
therapy.
- Patients who develop increased transaminase levels should be monitored until the abnormalities
resolve .
If the liver function values should increase to more than triple the normal level and persist over longer
period , dose reduction or withdrawal of Atrovastatin is recommended .
*Skeletal muscle effects :-
Atorvastatin may in rare occasion affect the skeletal muscel and cause myalgia , myositis and myopthy .
The increasea of muscle enzyme (CPK) in blood Should be examined if it remains clearly elevated over
a longer period the dose should be reduced or withdrawn.
Whilst on treatment:
- Patients must be asked to promptly report muscle pain, cramps, or weakness especially if accompanied
by malaise or fever.
- If such symptoms occur whilst patients is receiving treatment with Atorvastatin, their CPK levels should
be measured. If these level are found to be significantly elevated (>5 times ULN), treatment should be stopped.
- If muscular symptoms are severe and cause dialy discomfort, even if the CPK levels are elevated to ≤
5 × ULN,treatment discontinuation should be considered.If symptoms resolve and CPK levels return
to normal, than re-introduction of Atorvastatin or introduction of an alternative statin may be
considered at the lowest dose and with close monitoring.
- Atorvastatin must be discontinued if cilincally significant elevation of CPK levels (> 10 × ULN )
occur, or if rhabdomyolysis is diagnosed or suspected.